Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer

Parikh RB, Adamson BJS, Khozin S, Galsky MD, Baxi SS, Cohen A, Mamtani R

September 2019

Manuscript

JAMA

Flatiron-authored

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T

September 2019

Manuscript

Gastric Cancer

Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC

September 2019

Manuscript

Pharmacoeconomics Open

Validation of diagnosis codes to identify side of colon in an electronic health record registry

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ

August 2019

Manuscript

BMC Medical Research Methodology

Flatiron-authored

Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP

August 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW

August 2019

Manuscript

Journal of Comparative Effectiveness Research

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP

August 2019

Manuscript

Cancer

Flatiron-authored

July 2019

Manuscript

Journal of Clinical Oncology

Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R

July 2019

Manuscript

European Urology

Flatiron-authored

July 2019

Manuscript

Clinical Pharmacology and Therapeutics

An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J

July 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

July 2019

Manuscript

Medicine

June 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

ISPOR, the FDA, and the evolving regulatory science of medical device products

O'Neill T, Miksad R, Miller D, Maloney L, John A, Hiller C, Hornberger, J

June 2019

Manuscript

Value in Health

Flatiron-authored

June 2019

Manuscript

Immunotherapy

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC

Castellanos E, Snider J, Ali SM, Backenroth D, Albacker LA, Murugesan K, Li G, Frampton GM, Alexander BM, Carson KR

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Impact of Oncology Care Model reporting requirements on quality of care

Castellanos E, Orlando A, Hamrick J, Ma X, O'Connell G, Meropol NJ, Adamson B.

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy

Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Genomic characterization of lung tumors and metastatic sites in advanced NSCLC

Willard MD, Smyth EN, Tiu RV, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents

Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev NA, Gore S, Ma X, Gross CP, Davidoff AJ, Neparidze N

June 2019

Abstract

ASCO Annual Meeting

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder

Garcia R, Dwyer A, Worrall S, Heery CR, Deming DA, Benson AB, Davis A.

June 2019

Abstract

ASCO Annual Meeting

A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status

McLaurin K, Dalvi T, Collins JM, Nordstrom BL, McCutcheon S, Bennett JC, Murphy BR, Singhal PK, Briceno JM

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma

Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Li L, Tang S, Reichman W, Kauffman MG, Shah JJ, Shacham S, Lonial S.

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer

Batus M, Stefaniak VJ, Molife C, Clarke JM, Winfree KB, Mitchell L, Cui ZL, Bonom PD

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma

Feld E, Harton J, Meropol NJ, Adamson B, Parikh RB, Galsky MD, Cohen AB, Narayan V, Christodouleas JP, Vaughn DJ, Hubbard RA, Mamtani R

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases

Smyth EN, Tiu RV, Willard MD, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

May 2019

Manuscript

Advances in Therapy

Flatiron-authored